Edition:
United States

Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

517.05INR
17 Nov 2017
Change (% chg)

Rs8.40 (+1.65%)
Prev Close
Rs508.65
Open
Rs510.00
Day's High
Rs521.90
Day's Low
Rs510.00
Volume
366,214
Avg. Vol
484,349
52-wk High
Rs730.75
52-wk Low
Rs433.15

Chart for

About

Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New... (more)

Overall

Beta: 0.12
Market Cap(Mil.): Rs1,220,169.00
Shares Outstanding(Mil.): 2,399.31
Dividend: 3.50
Yield (%): 0.69

Financials

  Industry Sector
P/E (TTM): -- 31.18 15.80
EPS (TTM): -- -- --
ROI: -- 15.02 12.07
ROE: -- 16.37 16.02

BRIEF-Sun Pharma Industries MD says no new updates on Halol; awaiting FDA re-inspection of plants‍​

Nov 14 Sun Pharmaceutical Industries managing director Dilip Shanghvi says:

Nov 14 2017

UPDATE 1-India's Sun Pharma posts profit dive on U.S. pricing pressure

* Q2 profit down 59 pct * Indian sales rise 11 pct * U.S. sales down 44 pct (Adds detail, executive comment) Nov 14 India's largest drugmaker Sun Pharmaceutical Industries reported a 59 percent plunge in second-quarter profit on Tuesday, hurt by generics pricing pressure in the United States. Along with other Indian drugmakers, Sun Pharma has had sales dented by rising competition in the generics market and greater pricing scrutiny in the United States,

Nov 14 2017

BRIEF-Sun Pharmaceutical Industries approves scheme of arrangement between co & Sun Pharma Global FZE

* Says approves scheme of arrangement among Sun Pharma Global FZE & co‍​

Nov 14 2017

India's Sun Pharma Q2 profit dives 59 pct

Nov 14 India's largest drugmaker, Sun Pharmaceutical Industries Ltd , posted a 59 percent plunge in second-quarter profit on Tuesday, but beat estimates. Profit came in at 9.12 billion rupees ($139.48 million) in the quarter ended Sept. 30, compared with 22.35 billion rupees a year ago, the company said. http://bit.ly/2zVVJbv Analysts on average had expected a profit of 8.27 billion rupees, according to Thomson Reuters data. ($1 = 65.3850 Indian rupees) (R

Nov 14 2017

BRIEF-India's Sun Pharmaceutical Industries Sept-qtr consol profit falls 59 pct

* Sept quarter consol net profit 9.12 billion rupees versus profit of 22.35 billion rupees last year

Nov 14 2017

BRIEF-Sun Pharmaceutical Industries gets U.S.FDA nod for generic Coreg CR‍​

* Says gets U.S.FDA nod for generic Coreg CR‍​ Source text: http://bit.ly/2gKhXoX Further company coverage:

Oct 26 2017

BRIEF-Sun Pharmaceutical Industries says unit raises shareholding in Ranbaxy Malaysia Sdn Bhd

* Unit agreed to increase shareholding in Ranbaxy Malaysia Sdn Bhd via purchase of 666,985 shares of Ranbaxy Malaysia Source text - http://bit.ly/2g5YoTO Further company coverage:

Oct 12 2017

Indian shares inch up; Sun Pharma rises

* Sun Pharma among top gainers after FDA ends inspection at plant

Oct 12 2017

BRIEF-Sun Pharma Industries says U.S. FDA inspection closed at co's Dadra facility‍​

* Says U.S. FDA inspection at co's Dadra facility‍​ is closed Source text - http://bit.ly/2y97tpz Further company coverage:

Oct 11 2017

Pfizer sues Sun Pharmaceuticals to block generic Bosulif

Pfizer Inc has filed a lawsuit seeking to block a generic manufacturer from selling a cheaper version of leukemia drug Bosulif.

Sep 28 2017

Earnings vs. Estimates